Two weeks after the first administration of 300 mg ocrelizumab, CD3+CD20+ T cells (representing at baseline almost 20% of the CD20+ cells) were rapidly and efficiently depleted from peripheral blood of MS patients (63) These findings were confirmed by another study showing a marked decrease in both absolute numbers and percentages of CD20+ T cells relative to CD3+ T cells six months after ocrelizumab start, being the relative reduction significant in both CD4+ and CD8+ subsets (65). Here, CD4 is linked to myeloid sarcoma.